Phase Ib/II, neoadjuvant pembrolizumab (200 mg intravenously every 3 weeks) and high-dose IFNα-2b (intravenously 20 MU/m2/day, 5 days/week for 4 weeks, followed subcutaneously 10 MU/m2/day, 3 days/week for 2 weeks) were given to resectable stage III melanoma in two cycles before surgery (30 patients). Here, IFNA2 is linked to melanoma.